Pennsylvania is currently home to 3309 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Philadelphia, Pittsburgh, Hershey and Allentown. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Neratinib and Fam-Trastuzumab Deruxtecan in Advanced Gastro-esophageal Cancer Patients
NCT05274048
Recruiting
This is Phase 1 dose finding trial with potential dose expansion to evaluate the safety, toxicity, recommended phase 2 dose (RP2D), and maximum tolerated dose (MTD) of Neratinib plus TDxD using a standard 3+3 dose escalation design in patients with metastatic or unresectable gastro-esophageal cancer that are HER2-overexpressing (IHC 3+ or IHC2+/ISH+) and any other gastrointestinal cancer with HER2 expression with IHC3+. Patients must have progressed or been intolerant of at least one prior line... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/30/2025
Locations: Fox Chase Cancer Center, Philadelphia, Pennsylvania
Conditions: Gastric Cancer, Gastrointestinal Cancer, HER2 Gene Mutation
Register for Updates
Pembrolizumab, Olaparib, and Temozolomide for People with Glioma
NCT05188508
Recruiting
This study will test the safety and effectiveness of a combination of pembrolizumab, olaparib, and temozolomide to see how well these drugs work when given together in people with a glioma that either did not respond to previous treatment or came back after treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/30/2025
Locations: Lehigh Valley Health Network (Data Collection Only), Allentown, Pennsylvania
Conditions: Glioma
Register for Updates
CPX-351 for the Treatment of Secondary Acute Myeloid Leukemia in Patients Younger Than 60 Years Old
NCT04269213
Recruiting
This phase II trial studies how well liposome-encapsulated daunorubicin-cytarabine (CPX-351) works in treating patients with secondary acute myeloid leukemia who are younger than 60 years old. Drugs used in chemotherapy, such as CPX-351, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
Gender:
ALL
Ages:
Between 18 years and 59 years
Trial Updated:
01/30/2025
Locations: Allegheny Health Network Cancer Institute - West Penn Hospital, Pittsburgh, Pennsylvania
Conditions: Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia
Register for Updates
Registry of Patients With a Diagnosis of Spinal Muscular Atrophy (SMA)
NCT04174157
Recruiting
Spinal muscular atrophy (SMA) is a neurogenetic disorder caused by a loss or mutation in the survival motor neuron 1 gene (SMN1) on chromosome 5q13, which leads to reduced SMN protein levels and a selective dysfunction of motor neurons. SMA is an autosomal recessive, early childhood disease with an incidence of 1:10,000 live births. SMA is the leading cause of infant mortality due to genetic diseases. The purpose of this registry is to assess the long term outcomes of patients with SMA in the c... Read More
Gender:
ALL
Ages:
All
Trial Updated:
01/30/2025
Locations: Penn State Hershey, Hershey, Pennsylvania
Conditions: Spinal Muscular Atrophy (SMA)
Register for Updates
Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma
NCT04031677
Recruiting
This is a multicenter, randomized, open label phase lll trial to assess whether preoperative chemotherapy, as an adjunct to curative-intent surgery, improves the prognosis of high risk DDLPS (dedifferentiated Liposarcoma) and LMS (Leiomyosarcoma) patients as measured by disease free survival. After confirmation of eligibility criteria, patients will be randomized to either the standard arm or experimental arm.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/30/2025
Locations: Saint Vincent Hospital, Erie, Pennsylvania
Conditions: Retroperitoneal Sarcoma, Liposarcoma, Leiomyosarcoma
Register for Updates
Flu Infection at UPHS
NCT06807840
Recruiting
Cellular and humoral immune responses in individuals with active influenza infection will be assessed. Each year, up to 50 participants will be enrolled. The investigators hypothesize that influenza infection will elicit mostly memory immune responses rather than de novo immune responses to infection.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/29/2025
Locations: Penn Presbyterian Medical Center, Philadelphia, Pennsylvania
Conditions: Influenza Human
Register for Updates
A Study of OnCARlytics (CF33-CD19) in Combination with Blinatumomab in Adults with Advanced or Metastatic Solid Tumors (OASIS)
NCT06063317
Recruiting
This is an open-label, dose escalation and dose expansion, multi-center phase I study evaluating the safety and tolerability of CF33-CD19 administered intravenously (IV) or intratumorally (IT) in combination with blinatumomab in adults with advanced or metastatic solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/29/2025
Locations: University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania
Conditions: Solid Tumor, Adult
Register for Updates
Pregabalin Plus Lofexidine for the Outpatient Treatment of Opioid Withdrawal
NCT05995535
Recruiting
A placebo-controlled trial in which male and female outpatients with an opioid use disorder who express interest in extended-release injectable naltrexone (XR-NTX) are randomized 1:1 to lofexidine/pregabalin or lofexidine/pregabalin placebo for withdrawal management and offered XR-NTX if after completing withdrawal.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/29/2025
Locations: University of Pennsylvania, Treatment Research Center, Philadelphia, Pennsylvania
Conditions: Opiate Withdrawal Syndrome, Opioid Use
Register for Updates
Improving Survival for Metastatic Lobular Breast Cancer (PLUMB Registry)
NCT05964504
Recruiting
This is a prospective observational registry for patients with invasive lobular carcinoma (ILC) of the breast. After the first 1cohort is enrolled, the collected data will be utilized to develop an ILC specific response assessment tool.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/29/2025
Locations: Abramson Cancer Center, Philadelphia, Pennsylvania
Conditions: Metastatic Breast Cancer, Lobular Breast Carcinoma
Register for Updates
Study of Tucatinib and Doxil in Participants with Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer
NCT05748834
Recruiting
This clinical trial is evaluating tucatinib in combination with Doxil in participants with human epidermal growth factor 2 positive (HER2+) locally advanced or metastatic breast cancer. The main goals of this study are to: * Learn how well the combination of tucatinib and Doxil works * Learn more about the side effects of the combination of tucatinib and Doxil
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/29/2025
Locations: Alliance Cancer Specialists, Bensalem, Pennsylvania
Conditions: Breast Cancer
Register for Updates
Neoadjuvant PD-1 Blockade in Resectable Merkel Cell Carcinoma
NCT05496036
Recruiting
The main purpose of this study is to determine the response of Merkel cell carcinoma to pembrolizumab before surgery and to determine whether it further reduces the risk for disease recurrence. Another purpose of this study is to look at the side effects that occur when the experimental drug pembrolizumab is given to people with Merkel cell carcinoma before and after their standard of care surgery to remove the Merkel cell carcinoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/29/2025
Locations: Penn Medicine, Philadelphia, Pennsylvania
Conditions: Merkel Cell Carcinoma
Register for Updates
Persona Revision Knee System Outcomes
NCT04821154
Recruiting
The study will evaluate the performance, clinical benefits and safety of the Persona Revision Knee System in patients who have received primary or revision total knee arthroplasty (TKA) treatment. This will be done using a multicenter, single-arm, consecutive series, retrospective cohort study with prospective follow-up.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/29/2025
Locations: Penn Medicine/ Lancaster General Health, Lancaster, Pennsylvania
Conditions: Arthroplasty Complications, Infection, Knee Disease, Knee Osteoarthritis
Register for Updates